AVEVA
25.5.2023 10:26:27 CEST | Business Wire | Press release
AVEVA, a global leader in industrial software, has further strengthened its leadership team announcing four new senior executive roles as the company drives forward its new business model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005082/en/
Iju Raj, Executive Vice President of R&D, AVEVA (Photo: Business Wire)
The news follows the announcement in March of the company’s new Chief Executive Officer Caspar Herzberg, who took over the top job at AVEVA from Peter Herweck, now its chairperson. Herweck officially started as CEO of parent company Schneider Electric on May 4.
Sue Quense, currently AVEVA’s Senior Vice President of Americas, takes on the newly created role of Chief Commercial Officer. Quense, based in Philadelphia, USA, has spent more than three decades in software sales leadership roles. She was a driving force at OSIsoft, which merged with AVEVA in 2021 to meet the expanding industrial intelligence of global enterprises and accelerate the evolution of the connected industrial economy.
Marco Mueller, a long-time technology industry leader, joins AVEVA as Chief Marketing Officer and will be based in London, UK. He was formerly Senior Vice President Global Demand Marketing at ServiceNow, a leading cloud computing platform company headquartered in California’s Silicon Valley, for two and half years. Before that, Marco spent more than a decade in marketing executive roles with SAP, a market leader in enterprise application software where he led marketing teams across the globe. He began his career as a management consultant at Accenture in the high tech and consumer products industries.
With AVEVA’s goal to support end-to-end product innovation, the research & development (R&D) function and project delivery services will come together with the Business Units and Portfolio Management teams under the leadership of Rob McGreevy, Chief Product Officer.
Iju Raj, who has spent the last five years heading up AVEVA’s cloud platform, takes on the role of Executive Vice President for R&D and will report to McGreevy. Based in India, Raj will be responsible for the day-to-day leadership and operations of R&D, driving efficient development processes, programs, and software innovation.
Caspar Herzberg, CEO of AVEVA, said: “This is a pivotal moment in AVEVA’s 55-year heritage as a leading innovator of software and industrial sustainability. We are undergoing a portfolio-wide transition to a subscription-based business model, and I’m delighted to be adding such expertise and experience to the top table to further strengthen our growth plans.
“To accelerate access to modern solutions and meet dynamic business needs, customers can trade-in their existing perpetual licenses for subscriptions spanning any mix of cloud, hybrid, and on-premises solutions across the design-operate-optimize industrial lifecycle. Sue, Marco, Rob and Iju will be instrumental in further enhancing our leadership team and driving growth.”
- ENDS –
Notes to Editor
About AVEVA
AVEVA is a global leader in industrial software, sparking ingenuity to drive responsible use of the world’s resources. The company’s secure industrial cloud platform and applications enable businesses to harness the power of their information and improve collaboration with customers, suppliers, and partners.
Over 20,000 enterprises in over 100 countries rely on AVEVA to help them deliver life’s essentials: safe and reliable energy, food, medicines, infrastructure and more. By connecting people with trusted information and AI-enriched insights, AVEVA enables teams to engineer efficiently and optimize operations, driving growth and sustainability.
Named as one of the world’s most innovative companies, AVEVA supports customers with open solutions and the expertise of more than 6,400 employees, 5,000 partners and 5,700 certified developers. The company, which has operations around the globe, is headquartered in Cambridge, UK. Learn more at www.aveva.com.
Copyright © 2023 AVEVA Solutions Limited. All rights reserved. AVEVA Solutions Limited is owned by AVEVA Group. AVEVA, the AVEVA logos and AVEVA product names are trademarks or registered trademarks of AVEVA Group or its subsidiaries in the United Kingdom and other countries. Other brands and product- names are the trademarks of their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
